Improve constipation with fecal transplant
- Trial ID
- NCT06388863
- Official Title
- Evaluation of the Efficacy and Safety of Fecal Microbiota Transplantation for Parkinson's Disease Patients With Constipation
- Goal
- Improve constipation with fecal transplant
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Shanghai Zhongshan Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 76 participants
- Conditions
- Parkinson Disease
- Interventions
- Healthy donor-derived FMT capsule, Placebo capsule
Plain-Language Summary
Looking to see if giving healthy donor gut bacteria can relieve the chronic constipation many people with Parkinson's have, while checking safety and any ripple effects on Parkinson's symptoms. Treatment is oral capsules of donor-derived fecal microbiota or placebo, intended to reshape the gut microbiome to normalize bowel movements and reduce gut inflammation, and because gut bacteria can change levodopa absorption the trial requires stable Parkinson's medications so any changes can be tracked. Enrolling adults 40 to 75 with diagnosed PD at Hoehn-Yahr stage 1 to 3 who meet specific chronic constipation criteria, have been on stable anti-Parkinson meds, and who do not have recent antibiotics, major systemic illness, immunodeficiency, or other listed exclusions.
Locations
- 180 Fenglin Road, Shanghai, Shanghai Municipality, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Healthy donor-derived FMT capsule. Looking to see if giving healthy donor gut bacteria can relieve the chronic constipation many people with Parkinson's have, while checking safety and any ripple effects on Parkinson's symptoms. Treatment is oral capsules of donor-derived fecal microbiota or placebo, intended to reshape the gut microbiome to normalize bowel movements and reduce gut inflammation, and because gut bacteria can change levodopa absorption the trial requires stable Parkinson's medications so any changes can be tracked. Enrolling adults 40 to 75 with diagnosed PD at Hoehn-Yahr stage 1 to 3 who meet specific chronic constipation criteria, have been on stable anti-Parkinson meds, and who do not have recent antibiotics, major systemic illness, immunodeficiency, or other listed exclusions.
- Who can participate?
- Participants must be between 40 Years and 75 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 10 months.